Washington Business Journal -- GenVec Inc. rallied to its highest level in almost a year and a half after saying it will keep its Nasdaq Stock Market listing. The Gaithersburg-based company, developing a treatment for pancreatic cancer, was warned in September it was a risk of being delisted from Nasdaq because its stock price had traded below the $1 per share minimum for too long. Nasdaq notified the company Thursday that it had regained compliance and would keep its listing.
